Jefferies reiterates Buy on Gilead stock, sees lower IRA impact
Jefferies maintained a Buy rating and $196 price target for Gilead Sciences (GILD), citing a potential $1.5B revenue headwind from Biktarvy's pricing under the Inflation Reduction Act in 2028, but expects offsets to reduce this impact. Gilead reported Q3 2026 earnings of $2.55 per share and $8.3B revenue, exceeding estimates. Analysts UBS, Bernstein, TD Cowen, and BMO raised their price targets following strong results.
How this was made
The 30-second read
Why it matters
The combination of an earnings beat and an upgraded price target is likely to drive short-term buying interest, while the discussion of IRA offsets may temper longer‑term expectations.
Market read
Gilead's earnings beat and analyst upgrade provide a fresh catalyst for the stock, making the news highly relevant for traders.
What to watch
Potential regulatory changes to the IRA pricing methodology could alter the projected offsets.
Background
Jefferies issued a fresh analyst note reiterating a Buy rating on Gilead Sciences, citing a $196 price target and a lower-than-expected revenue hit from the Inflation Reduction Act pricing rules, alongside a recap of the company's Q3 2026 earnings beat.
Ticker impact
Jefferies reiterated a Buy rating with a $196 price target and highlighted a lower-than-expected IRA impact on net revenue, following Gilead's strong Q3 2026 earnings beat.
likely upward pressure as the market prices in the higher target and reduced revenue headwind
The new price target of $196 represents ~17% upside from current price and the earnings beat reduces perceived risk.
Market effects
Positive earnings and guidance may lift the broader biotech/pharma sector.
U.S. market may see modest gains in healthcare stocks.
Limited to U.S. investors; no immediate global macro effect.
Counterpoint
If the IRA pricing impact is larger than estimated, revenue could be pressured, limiting upside.
Key entities
- companyGilead Sciences
U.S. biotech firm reporting Q3 2026 earnings and receiving an analyst upgrade.
- analyst_firmJefferies
Equity research firm that reiterated a Buy rating and set a new price target.
